-
MOVE-FA Study for PTC-743
Enrollment is open at sites in the U.S., Canada, and Australia.
MOVE-FA is a Phase 2/3 interventional study that will monitor the safety and efficacy of the drug Vatiquinone. This 2-year study is sponsored by PTC Therapeutics. Eligibility criteria include:
-Genetically confirmed FA with two GAA repeat expansions (currently, point mutations and deletions are excluded from the study)
-Children ages 7-17 and Adults age 18 and older
-Ability to walk 10 feet in one minute (can use assitive devices of cane or walker; no wheelchair)
-Be able to swallow capsules
-Not have participated in another interventional study in the 2 months prior to enrollment in MOVE-FAInformation on MOVE-FA and contacts for study coordinators can be found below: bit.ly/36YC9t6
Sorry, there were no replies found.
Log in to reply.